Skip to Main Content
Table 2

Risk of breast cancer by CYP1A1-MspI polymorphism and plasma levels of lipid-adjusted PCBs among all women and postmenopausal women only

CYP1A1 genotypeTertile PCBsa (cut-offs μg/g)CasesControlsRR (95% CI)Multivariate RRb (95% CI)
Postmenopausal women (293 case/control pairs)      
 WT/WT 1 (0.13–0.47) 79 78 1.00 1.00 
 WT/WT 2 (0.47–0.67) 73 79 0.94 (0.61–1.46) 1.00 (0.62–1.60) 
 WT/WT 3 (0.67–1.99) 85 82 1.08 (0.67–1.75) 1.18 (0.69–2.01) 
 Variantsc 1 (0.13–0.47) 14 19 0.70 (0.32–1.54) 0.53 (0.27–1.23) 
 Variants 2 (0.47–0.67) 24 20 1.22 (0.63–2.38) 1.37 (0.67–2.79) 
 Variants 3 (0.67–1.99) 18 15 1.27 (0.59–2.76) 1.08 (0.47–2.48) 
 Test for interactiond    0.47 0.22 
All women (367 case/control pairs)      
 WT/WT 1 (0.13–0.46) 106 97 1.00 1.00 
 WT/WT 2 (0.46–0.65) 86 99 0.81 (0.54–1.21) 0.84 (0.54–1.30) 
 WT/WT 3 (0.65–1.99) 102 103 0.93 (0.60–1.45) 1.00 (0.62–1.63) 
 Variantsb 1 (0.13–0.46) 19 25 0.70 (0.36–1.35) 0.63 (0.31–1.28) 
 Variants 2 (0.46–0.65) 32 25 1.16 (0.65–2.09) 1.24 (0.66–2.33) 
 Variants 3 (0.65–1.99) 22 18 1.16 (0.58–2.34) 0.94 (0.44–2.01) 
 Test for interaction    0.24 0.21 
CYP1A1 genotypeTertile PCBsa (cut-offs μg/g)CasesControlsRR (95% CI)Multivariate RRb (95% CI)
Postmenopausal women (293 case/control pairs)      
 WT/WT 1 (0.13–0.47) 79 78 1.00 1.00 
 WT/WT 2 (0.47–0.67) 73 79 0.94 (0.61–1.46) 1.00 (0.62–1.60) 
 WT/WT 3 (0.67–1.99) 85 82 1.08 (0.67–1.75) 1.18 (0.69–2.01) 
 Variantsc 1 (0.13–0.47) 14 19 0.70 (0.32–1.54) 0.53 (0.27–1.23) 
 Variants 2 (0.47–0.67) 24 20 1.22 (0.63–2.38) 1.37 (0.67–2.79) 
 Variants 3 (0.67–1.99) 18 15 1.27 (0.59–2.76) 1.08 (0.47–2.48) 
 Test for interactiond    0.47 0.22 
All women (367 case/control pairs)      
 WT/WT 1 (0.13–0.46) 106 97 1.00 1.00 
 WT/WT 2 (0.46–0.65) 86 99 0.81 (0.54–1.21) 0.84 (0.54–1.30) 
 WT/WT 3 (0.65–1.99) 102 103 0.93 (0.60–1.45) 1.00 (0.62–1.63) 
 Variantsb 1 (0.13–0.46) 19 25 0.70 (0.36–1.35) 0.63 (0.31–1.28) 
 Variants 2 (0.46–0.65) 32 25 1.16 (0.65–2.09) 1.24 (0.66–2.33) 
 Variants 3 (0.65–1.99) 22 18 1.16 (0.58–2.34) 0.94 (0.44–2.01) 
 Test for interaction    0.24 0.21 
a

Cut-offs for tertiles based on the appropriate control distribution, all women or postmenopausal only depending on the analysis.

b

RR adjusted for history of breast cancer in mother or a sister, a history of benign breast disease, age at menarche (<12 years, 12 years, >12 years), body mass index (<25, 25–29, 30+ kg/m2), number of children, and age at birth of first child (nulliparous, 1–2 children and age ≤24 at first birth, 1–2 children and age >24 at first birth, ≥3 children and age ≤24 at first birth, and ≥3 children and age >24 at first birth), and duration of lactation (0, 1–6 months, and >6 months).

c

Variants are all women who are either heterozygous or homozygous for the variant allele.

d

Test for interaction, likelihood ratio test comparing model with cross-classified variables with model with main effects only.

Close Modal

or Create an Account

Close Modal
Close Modal